611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
As in Adults, Minority Kids Hit Hardest by COVID-19Simple Test Shows Which Face Masks Are BestBeware of Hand Sanitizers Containing MethanolWhat Athletes Should Know About COVID-19, Heart Damage and Working OutCOVID-19 Causing More Stress in America Than Other Nations: SurveyWill Your Kid Play School Sports This Fall? Here's Some Guidance on Doing It SafelyScientists Call for Broader Use of Faster COVID TestsTwo Common Nutrients Might Keep Vertigo at BayPeople Are Dying, Going Blind After Drinking Hand Sanitizer, CDC WarnsMore Social Media Use, More Fake COVID NewsSkip the 'Maskne,' Not the MaskObesity Ups Odds for Severe COVID-19, But Age MattersSeven States Join Pact to Speed Coronavirus TestingStudy Casts Doubt on Value of Cholesterol DrugsCOVID-19 Fears Had Sick, Injured Americans Avoiding ERsCancer Diagnoses Plunge as Americans Avoid Screening During PandemicMysterious Paralyzing Illness in Kids Is Set to Return, CDC WarnsMany Older Americans Staying Strong in the PandemicCoronavirus Cases Now Climbing in the MidwestCould the First Drug That Slows Arthritis Be Here?Schools Can Reopen Safely If Precautions in Place, Australian Study ShowsFace Masks, Yes, But Don't Forget Hand-Washing TooEven With PPE, Risk of COVID-19 Still High for Frontline WorkersCoronavirus Pandemic Becoming Far More Widespread, Birx SaysGuard Against Lyme Disease This SummerKids 'Efficient' Transmitters as COVID-19 Raced Through a Georgia Summer CampCollege Students Will Need COVID Tests Every 2-3 Days for Campus Safety: StudyAHA News: Sustained High Blood Pressure May Damage Brain VesselsAnother Side Effect of COVID-19 -- Lasting Hearing Problems?Pandemic Could Complicate Hurricane SeasonStudy Reveals How Coronavirus Travels IndoorsNew Study Sheds Doubt on Notion Kids Aren't COVID-19 SpreadersAHA News: Are Virtual Doctor Visits Safe for Discharged Heart Failure Patients?Double Lung Transplants Save Lives of Sickest COVID PatientsGynecological Cancers Not a Risk for Severe COVID-19: Study11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWildfire Pollution Puts Kidney Patients at RiskAmerica's Progress Against Early Cardiovascular Death Is SlowingAHA News: 5 Easy Ways to Keep Tabs on Heart HealthGene Study Shows How Coronavirus Swept Through the Diamond PrincessOne Disease Mosquitoes Don't Spread: CoronavirusU.S. Coronavirus Death Toll Surges Past 150,000Do Bedbugs Dirty the Air Inside Your Home?AHA News: New Test May Predict Who Develops Certain Type of Heart FailureLess Smoking, Drinking Means Fewer Hip Fractures for AmericansYet Another Study Finds Vaccines Are SafeCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationSurvivors' COVID Antibodies May Provide a Powerful GiftConcussion Ups Odds for Many Brain ConditionsFinal Coronavirus Vaccine Trials Get Underway
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves Oxbryta for Treatment of Sickle Cell Disease


HealthDay News
Updated: Nov 26th 2019

new article illustration

TUESDAY, Nov. 26, 2019 (HealthDay News) -- Oxbryta (voxelotor) has been granted accelerated approval for the treatment of sickle cell disease in patients ages 12 years and older, the U.S. Food and Drug Administration announced Monday.

Oxbryta is the first approved treatment for sickle cell disease that directly inhibits the root cause of the disease, sickle hemoglobin polymerization, according to a company press release. Nonclinical studies of Oxbryta have shown the drug inhibits red blood cell sickling and improves red blood cell deformability and the ability of blood to flow. The recommended dosage of Oxbryta is 1,500 mg orally once daily with or without food. For severe hepatic impairment, the recommended dosage is 1,000 mg orally once daily.

Approval of Oxbryta was based on clinical data from the HOPE Study of 274 patients with sickle cell disease who received 1,500 or 900 mg of Oxbryta (90 and 92 patients, respectively) or placebo (92 patients). After 24 weeks of treatment, 51.1 percent of patients who received 1,500 mg of Oxbryta achieved an increase of greater than 1 g/dL in hemoglobin response rate compared with 6.5 percent of patients who received placebo.

Commonly reported side effects with Oxbryta include headache, diarrhea, abdominal pain, nausea, fatigue, rash, and fever.

Approval was granted to Global Blood Therapeutics. The drug is expected to be available through a specialty pharmacy partner network within two weeks.

More Information